Highlights Gamida Cell Ltd.

Equities

GMDA

IL0011552663

Market Closed - OTC Markets Other stock markets 03:55:03 2024-05-08 pm EDT			5-day change	1st Jan Change
0.0145 ^USD	-6.45%		-6.45%	-96.49%

Apr. 10	Gamida Cell Ltd.(NasdaqGM:GMDA) dropped from S&P Global BMI Index	CI
Apr. 05	Gamida Cell Ltd.(OTCPK:GMDA.Q) dropped from NASDAQ Composite Index	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Gamida Cell Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 27	CI
Gamida Cell Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 14	CI
Gamida Cell Presents New Data on Allogeneic Stem Cell Therapy Omidubicel and Natural Killer (NK) Cell Therapy Candidate GDA-201 at Society for Immunotherapy of Cancer Annual Meeting	Nov. 04	CI
Gamida Cell Ltd. Reports Preliminary Data from Phase 1 Study of Natural Killer Cell Therapy Candidate GDA-201	23-10-16	CI
Gamida Cell Ltd. Announces First Patient Receives Omisirge (Omidubicel-Onlv)	23-09-27	CI
Gamida Cell Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-14	CI
Gamida Cell Ltd. Announces Publication in Prospective Sub- Study of the Phase 3 Clinical Trial for OmisirgeÂ®	23-07-11	CI
Gamida Cell Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-15	CI
Gamida Says Cell Therapy Omisirge Gets US FDA Clearance	23-04-17	MT
Gamida Cell Ltd. Announces Gamida Cell’s Allogeneic Cell Therapy Omisirge® (omidubicel-onlv) Receives FDA Approval	23-04-17	CI
Gamida Cell Shares Climb After US FDA Approves Cell Therapy Omisirge for Blood Cancer Patients	23-04-17	MT
US allows use of Gamida's therapy in blood cancer treatment	23-04-17	RE
US FDA approves Gamida's blood cancer therapy	23-04-17	RE
Gamida Cell 2022 Net Loss Narrows; Restructuring, Job Cuts Outlined; Shares Tumble	23-03-27	MT
Gamida Cell Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-27	CI
Data Presented on Gamida Cell’s Omidubicel, GDA-201 at the 2023 Tandem Meetings of ASTCT and CIBMTR	23-02-18	CI
Gamida Cell Ltd. and Lonza Netherlands B.V Agree to Terminate the Manufacturing Agreement	23-01-19	CI
Gamida Cell Says FDA Extended Target Action Date for Omidubicel Biologics License Application; Shares Drop	22-11-22	MT
Gamida Cell Ltd. Provides Regulatory Update on Omidubicel	22-11-21	CI
Gamida Cell Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-14	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Gamida Cell Ltd.

Equities

GMDA

IL0011552663

Highlights

Filters